No description available.

Porcine reproductive and respiratory syndrome virus (PRRSV) causes disease in swine and economic losses for swine producers. An inexpensive and effective method for removing PRRSV from air is required to reduce aerosol transmission of PRRSV. A laboratory study was used to assess the performance of air ionization at removing bioaerosols contaminated with PRRSV. Aerosol properties were measured with an Aerosol Particle Size Spectrometer and air samples were collected with SKC biosamplers. PRRSV RNA was quantified with RNA extraction and quantitative reverse transcription polymerase chain reaction. Reduction in aerosol concentrations ranged from 61 – 93% by number count and 68 – 96% by mass. Initial particle size distribution and airflow rate affected the performance of EPI Air at reducing aerosol concentrations. Air ionization was effective at removing PRRSV from the air. The PRRSV RNA concentrations were reduced by 68 – 90% and the average PRRSV RNA after ionization ranged from 154 – 4594 VGCN/m3.

Master of Science / Department of Biomedical Sciences / Raymond R. R. Rowland / Porcine Reproductive and Respiratory Syndrome Virus (PRSSV) is one of the most economically important diseases in the global swine industry, costing producers an estimated $660 million annually. PRRSV is genetically diverse with a low replication fidelity, due to it being an RNA virus, resulting in multitudes of isolates being produced. This virus has a tropism for cells of the monocyte/macrophage lineage. Cluster of Differentiation 163 (CD163) is considered the primary PRRSV receptor located on porcine alveolar macrophages (PAMs). CRISPR/Cas9 technology was utilized to knock out CD163 via a frameshift mutation, resulting in pigs of the CD163 Null genotype. Also, a domain of porcine CD163 was deleted and replaced with the insertion of a CD163 homolog of human-like domain and neomycin cassette to serve as a genetic marker. This swap resulted in pigs that possessed a CD163L1 domain 8 mimic of porcine homolog human CD163-like (hCD163L-1) of SRCR domain 8. Previous work has demonstrated that CD163 Null pigs were resistant to one genotype 2 PRRSV isolate. An in vivo study was performed to observe whether hCD163L-1 pigs were also resistant to infection. Various diagnostic tests were performed to determine the presence or absence of PRRSV viremia levels in serum, CD163 receptor surface expression levels on PAMs, IgG antibody levels and haptoglobin (Hp) levels in serum. hCD163L-1 pigs did not support genotype 1 PRRSV replication, but were susceptible to genotype 2 PRRSV infections. In addition, in vitro infection experiments were performed on PAMs and macrophages derived from peripheral blood mononuclear cells (PBMCs) to determine resistance to multiple isolates. hCD163L-1 macrophages showed reduced infection with genotype 2 and no infection with genotype 1 PRRSV during in vitro infections. Null PAMs and PBMCs derived macrophages did not support infection towards any isolate of either PRRSV genotype.

Master of Science / Diagnostic Medicine and Pathobiology / Carol R. Wyatt / Currently, porcine reproductive and respiratory syndrome virus (PRRSV) is the most economically significant disease affecting the swine industry. PRRSV is known for its restricted cell tropism, primarily infecting porcine alveolar macrophages (PAM) via receptor-mediated endocytosis. PRRSV infects only a portion of the PAM population both in vivo and in vitro, which suggests that not every macrophage is PRRSV-permissive. Three surface proteins that can act as receptors for PRRSV have been identified on PAM, however, little else is known about the regulation of macrophage tropism. Factors determining cellular permissibility or resistance to PRRSV infection remain largely uncharacterized, although a recent study from our laboratory demonstrated that 1) permissiveness to PRRSV infection increased with time in culture, 2) macrophages from infected pigs could be superinfected, and 3) addition of actinomycin D, which inhibits mRNA synthesis, blocked infection. These data suggest that a PRRSV-permissive subpopulation of cells derives from a non-permissive precursor population and depends on new mRNA synthesis. The current studies were designed to examine the effects of PRRSV on both infected and uninfected PAM cells in vitro, specifically focusing on the expression of MHC I, MHC II, CD14, CD163 and CD172a surface proteins. The results show upregulation of MHC II, CD14, CD163 and CD172a expression in PRRSV-infected cells and a downregulation on the uninfected cells within the PRRSV-inoculated cultures. The role of apoptosis in the PRRSV-inoculated cultures was investigated, with results showing similar, low levels of apoptosis in control and infected PAM. PAM cytokine responses to PRRSV and LPS were also examined and, although they were uniquely different relative to control PAM, no trends were detected in the responses of PAM infected with PRRSV compared to uninfected and classically stimulated PAM. These data confirm that there are at least two subsets of macrophages within the alveolar population and suggests that the subsets are differentially affected by PRRS virus. We also demonstrated that MHC I becomes undetectable on PAM as a result of the freezing process, and that PRRSV-permissiveness is greater in the cell population after freezing.

Porcine reproductive and respiratory syndrome virus (PRRSV) is a rapidly evolving virus that has significant economic and welfare implications for the pig industry. Vaccination strategies have proved largely ineffective in controlling PRRSV, in some cases even reverting to virulence. An increasing body of evidence suggests a host genetic basis for PRRSV resistance so there is a need to examine the role of host genetics in a biologically relevant in vitro cell culture system. However, PRRSV research is inhibited by the current scarcity of suitable in vitro culture systems. With the aim of developing a convenient in vitro model, porcine bone marrow-derived macrophages (BMDM) were evaluated as a PRRSV cell culture system. BMDM were found to be highly permissive to Type I PRRSV and amenable to genetic manipulation. BMDM proved to be excellent cells for virus production, producing significantly higher titres of PRRSV than commonly used alternative cell types. Surprisingly, PRRSV entry into BMDM was found to be independent of both the prototypic PRRSV receptors, CD163 and CD169, providing further evidence for the existence of alternate PRRSV entry mechanisms in primary cell types. To explore the genetics of pig susceptibility to PRRSV, network-based analysis of host transcriptional datasets, following PRRSV challenge, revealed important differences in co-regulated gene pathways between samples from pigs with different PRRSV-permissiveness. These pathways included genes with important, recently characterised, anti-pathogen activities. The incorporation of network-based transcriptional analysis and published genetic variation data led to the identification of a member of the guanlyate binding protein family, GBP-1, as a candidate host gene involved in controlling PRRSV replication. Overexpression of GBP-1 in BMDM revealed a significant anti-PRRSV function for this protein. Further investigation of published genetic variation in GBP-1 suggested a potential role of this gene in PRRSV tolerance. The results presented in this thesis provide evidence for an alternate PRRSV entry pathway in a biologically relevant cell type. The discovery of a highly PRRSV-infectable cell type with potential for genetic manipulation adds a useful new tool to the area of PRRSV research. The identification of GBP-1 as a novel anti-viral protein with a significant inhibitory effect on PRRSV infection, together with genetic variation in this gene, prompts further research into the genetic basis for PRRSV resistance.

Doctor of Philosophy / Department of Diagnostic Medicine/Pathobiology / Ying Fang / Porcine reproductive and respiratory syndrome virus (PRRSV) causes a tremendous economic loss in swine industry worldwide. The capabilities to evade host immune responses and to establish persistent infection are the two hallmark features of PRRSV infection. In this dissertation, the research was mainly focused on investigating the novel mechanisms underlying PRRSV transmission and persistence. In chapter 2, the research was focused on an alternative pathway of PRRSV intercellular transmission. Our data showed that intercellular nanotube connections can be utilized for cell-to-cell spreading the core infectious viral machinery (viral RNA, certain replicases and structural proteins) of PRRSV. Live-cell movies tracked the intercellular transport of a recombinant PRRSV that expressed green fluorescent protein (GFP)-tagged nsp2 in a receptor-independent manner. The cytoskeleton proteins F-actin and myosin-IIA were identified as co-precipitates with PRRSV nanotube associated proteins. Drugs inhibiting actin polymerization or myosin-IIA activation prevented nanotube formations and viral clusters in virus-infected cells. These data lead us to propose that PRRSV utilizes the host cell cytoskeletal machinery inside nanotubes for efficient cell-to-cell spread. This form of virus transport represents an alternative pathway for virus spread, which is resistant to the host humoral immune response. In chapter 3, we further showed that PRRSV infection could induce the formation of nanotubes between infected and uninfected cells following a ROS-dependent nanotube formation model. Co-culturing PRRSV-infected cells with uninfected cells rescued PRRSV-induced cell death. Mitochondrion was observed transferring from uninfected to PRRSV-infected cells. Importantly, impaired formation of nanotube or defective mitochondrion was unable to rescue infected cells from apoptosis/necrosis. Certain PRRSV proteins were detected to associate with mitochondria and transport from infected to uninfected cells through TNTs. Our results suggest that TNTs-transfer of functional mitochondria rescued PRRSV-infected cells from apoptosis/necrosis in the early stage of infection. On the other hand, mitochondria could be utilized as a cargo to transport viral materials for spreading the infection. In chapter 4, a novel mechanism s of PRRSV persistent infection has been studied. In this study, a cellular model of persistent infection was established. Strand-specific quantitative RT-PCR and RNase I treatment analysis showed that double-stranded RNA (dsRNA) conformation existed in persistently infected cells. This data has been further confirmed in vivo by performing two independent PRRSV persistence studies. Immunohistochemistry analysis showed that viral dsRNAs were detected aggregating inside the germinal centers of tonsils and lymph nodes from PRRSV persistence pigs, but RNA array analysis further showed that dsRNA in lymphoid tissues had limited ability to stimulate host antiviral responses during persistent infection stage. These results suggest that the PRRSV dsRNA functions as a mediator for viral persistence. The viral dsRNA persistence in germinal centers of lymphoid tissues may reveal a novel mechanism for PRRSV to escape antiviral immune responses. In summary, this study investigated two novel pathogenic mechanisms of PRRSV infection, which could provide insights on the development of effective control strategies.

Doctor of Philosophy / Department of Diagnostic Medicine/Pathobiology / Raymond R. R. Rowland / Infectious cDNA clones of PRRSV make it possible to construct marker viruses for the study of virus replication and pathogenesis. The nonstructural protein 2 (nsp2) of porcine reproductive and respiratory syndrome virus (PRRSV) is the single largest protein produced during virus replication. The cDNA of the pCMV-129 infectious PRRSV clone was modified by creating unique Mlu I and SgrA I restrictions sites at nucleotide (nt) positions 3,219 and 3,614, respectively: both located within the C-terminal region of nsp2. cDNAs coding for oligo- and polypeptide tags, including FLAG, enhanced green fluorescent protein (EGFP) and firefly luciferase were inserted into the newly created restriction sites. The results showed that only the EGFP-containing genomes were properly expressed and produced virus. EGFP fluorescence, but not EGFP immunoreactivity, was lost during passage of recombinant EGFP viruses in culture. Sequencing of a fluorescence-negative EGFP virus showed that the EGFP remained intact, except for the appearance of mutations that may affect chromophore formation. The results show that nsp2 can be a site for the expression of foreign proteins. Removal of the region between Mlu I and SgrA I sites resulted in a virus that contained a 131 amino acid deletion. The deleted region was replaced with EGFP or an eight amino acid influenza hemagglutanin (HA) tag. Recombinant viruses were used to infect pigs. Gross and micro-histopathology showed reduced pathogenesis when compared to the parent wild-type virus. The 131 amino acid peptide, when expressed as a recombinant protein and coated onto enzyme linked immunosorbent assay (ELISA) plates, was recognized by sera from pigs infected with wild-type virus, but not the deletion mutants. The results from this study show that nsp2 is a potential target for the development of marker vaccines that can differentiate infected from vaccinated animals (DIVA) and for virus attenuation.

Doctor of Philosophy / Department of Anatomy and Physiology / Jishu Shi / Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically important swine diseases worldwide that leads to severe reproductive failure in sows and high mortality in young pigs. Vaccination is currently the most effective way to control this disease. The protection ability provided by vaccines however is limited due to the large diversity of field PRRSV strains. In chapter 2, we compared immune responses induced by vaccination and/or PRRSV infection by using IngelVac® Modified Live PRRSV vaccine (MLV), its parental strain VR-2332, and the heterologous KS-06 strain. Our results showed that MLV provide complete protection to homologous virus and partial protection to heterologous challenge. The protection was associated with the levels of PRRSV neutralizing antibodies at the time of challenge. Besides developing new vaccines to combat PRRSV, adjuvants have been applied to PRRSV MLV vaccines to induce vaccination-mediated cross-protection against genetically dissimilar PRRSV strains. In chapter 3, we demonstrated that a commercial MontanideTM Gel01ST adjuvant provides enhanced protection to homologous PRRSV infection by regulating the production of PRRSV-specific antibodies. In chapter 4, we tested a novel peptide nanofiber hydrogel acting as a potent adjuvant for PRRSV MLV vaccines. We found that the hydrogel adjuvant enhanced vaccine efficacy by developing of higher titers of neutralizing antibodies and stronger IFN-γ cellular immune responses. Chinese highly pathogenic PRRSV (HP-PRRSV) variants were isolated in 2006 and they belong to genotype 2 of PRRSV. Compared with classic PRRSV, HP-PRRSV is characterized by robust proliferation ability and high morbidity/mortality with all ages of pigs. In chapter 5, we compared the difference of immune responses elicited by HV-PRRSV, a Chinese HP-PRRSV, and a US virulent strain of PRRSV NADC-20. Traditional PRRSV MLV vaccines developed in US offer no protection to HP-PRRSV. Vaccines specific to HP-PRRSV strains available in China provide protection to HP-PRRSV. In chapter 6, we demonstrated that pigs challenged with US NADC-20 strain were protected by vaccination with Chinese MLV HP-PRRSV vaccines. The availability of Chinese HP-PRRSV vaccines in North America may act to increase the preparedness of possible transmission of HP-PRRSV to North America.

<p>Porcine reproductive and respiratory syndrome virus (PRRSV) is estimated to cost the US swine industry $664 million in annual production losses. Therefore, the objective of this project was to evaluate the effect of MCFA on PRRSV replication using in vitro and in-vivo studies. The overarching hypothesis was that MCFA would inhibit or reduce viral replication of PRRSV infection in vitro and reduce viral load in-vivo. In the first experiment (Chapter 2), MARC-145 cells were used to determine the effects of individual MCFA (C6, C8, C10, and C12) exposure at concentrations ranging from 1-1000 µg/mL prior to and following inoculation of North American Type II (P-129) or European Type I (Lelystad) PRRSV. Viral replication was determined using FITC labeled IgG anti-PRRSV monoclonal antibody and TCID₅₀was calculated for each concentration. Data were analyzed using the Proc Mixed procedure of SAS. Incubation of MARC-145 cells with caproic acid (C6) at concentrations of 1-1000 µg/mL prior to and after inoculation with Type II North American (P129) or Type I European (Lelystad) PRRSV did not alter viral replication (<i>P</i> > 0.10). However, incubation of MARC-145 cells with caprylic (C8), capric (C10), and lauric (C12) acid prior to and after inoculation with Type I and Type II PRRSV did reduce viral replication at concentrations ranging from 100-1000 µg/mL. In general, the effective dose required to reduce (<i>P </i>< 0.05) viral replication (Log₁₀TCID₅₀/mL)decreased as MCFA chain length increased. In experiment 2 (Chapter 3), the use of MCFA combinations (C8:C10; C8:C12; C10:C12; and C8:C10:C12) to reduce viral replication of PRRSV in MARC-145 cells was investigated. The MCFA combinations were analyzed at six different concentrations ranging from 50-500 µg/mL with North American Type II (P-129) and European Type I (Lelystad) PRRSV. Viral replication was determined as described in experiment 1 (Chapter 2) using FITC labeled IgG anti-PRRSV monoclonal antibody and Log₁₀TCID₅₀/mL was calculated for each concentration. Data were analyzed using the Proc Mixed procedure of SAS. Incubation of MARC-145 cells with MCFA combinations prior to and after inoculation with Type II North American (P129) and Type I European (Lelystad) PRRSV resulted in reduced viral replication at MCFA concentrations of 200-500 µg/mL and was concentration dependent. Reduction of viral replication with MCFA was further evaluated by independently incubating MARC-145 cells or PRRSV. Results indicated that viral replication was reduced when MARC-145 cells were incubated with MCFA and not when PRRSV was incubated with MCFA. In experiment 3 (Chapter 4), 112 mixed sex pigs (PIC 1050 females x PIC 359 sire), weaned at 21 d of age, weighing 7.5 ± 0.68 kg, were used in a 33d PRRSV challenge study. Pigs were blocked by body weight and sex and randomly assigned to one of four treatments in a 2x2 factorial design with pigs receiving 0 or 0.30% MCFA in the diet and placebo or PRRSV inoculation. Following a 5 d adjustment to diets and rooms, pigs were inoculated with either a placebo (sterile PBS) or Type II North American (P129) PRRSV (1 x 10⁵,TCID₅₀/mL) given in 1 mL each intranasal and IM injection. Each room contained 4 pens with 7 pigs per pen and an equal ratio of barrows to gilts within treatment. Diets were formulated to meet or exceed all nutritional requirements (NRC, 2012) and were fed in 4 nursery phases. Feed budgets by phase were 1.13 kg/pig in phase 1, 2.72 kg/pig in phase 2, 6.35 kg/pig in phase 3, and phase 4 fed until the end of the experiment. MCFA (C8:C12) were mixed in a 1:1 ratio (wt:wt), and then mixed with finely ground corn to prepare a premix added to diets at 0.60% to provide 0.30% total MCFA. Control diets used soybean oil mixed with finely ground corn at the same 0.60% inclusion to keep ME levels constant across treatments. Body weights, feed intakes, blood samples, and temperatures were determined or collected on d 0, 3, 7, 10, 14, 21, and 28 post inoculation. Sections of tonsil, lung, and intestines were collected at d 10 post-inoculation from 1 pig per pen and at d 28 from all remaining pigs. Data were analyzed using the PROC Mixed procedure of SAS with pen as the experimental unit for growth and performance measurements and pig as the experimental unit for viral load analysis. Serum viral load confirmed PRRSV was only detectable in challenged pigs. Body weights were not different (<i>P</i> > 0.05) between treatments prior to d 14 post inoculation. Body weights from d 14 to 28 post inoculation were reduced (<i>P</i> < 0.05) in PRRSV infected pigs compared to non-infected pigs. Overall ADG and ADFI were reduced (<i>P </i>< 0.05) for PRRSV infected pigs compared to non-infected pigs by an average of 18 and 28%, respectively. Body temperatures were not different between treatments. Viral load measured in the lung was not different (<i>P </i>> 0.05) between PRRSV infected treatments. Tonsil viral load was not different (<i>P</i> > 0.10) between PRRSV treatments. However, there was a trend (<i>P</i> ≤ 0.10) for an effect of day post inoculation with control-fed, PRRSV-infected pigs having higher viral loads at d 10 post inoculation compared to d 28 post inoculation. Overall, no effects of MCFA on PRRSV viral load or performance were observed during the in-vivo trial. MCFA was effective at reducing viral replication of PRRSV in MARC-145 cells in vitro. However, the results could not be confirmed in the in-vivo experiment. Porcine alveolar macrophages should be used to confirm the in vitro inhibition of PRRSV replication observed in MARC-145 cells. In order to fully understand the application of MCFA to inhibit PRRSV infection in pigs, more studies should be conducted to evaluate the form of MCFA as well as viral inoculation with field strains of PRRSV. </p>

Background: The monitoring of infectious diseases like the porcine reproductive and respiratory syndrome (PRRS) using pen-wise oral fluid samples becomes more and more established. The collection of individual oral fluid, which would be useful in the monitoring of PRRSV negative boar studs, is rather difficult. The aim of the study was to test two methods for individual oral fluid collection from pigs and to evaluate the specificity of a commercial ELISA for detection of PRRSV antibodies in these sample matrices. For this reason, 334 serum samples from PRRSV negative pigs (group 1) and 71 serum samples from PRRSV positive pigs (group 2) were tested for PRRSV antibodies with a commercial ELISA. Individual oral fluid was collected with a cotton gauze swab from 311 pigs from group 1 and 39 pigs from group 2. Furthermore, 312 oral fluid samples from group 1 and 67 oral fluid samples from group 2 were taken with a self-drying foam swab (GenoTube). The recollected oral fluid was then analysed twice with a commercial ELISA for detection of PRRSV antibodies in oral fluid.